Maplight Therapeutics, INC Form 4 insider transactions

Chief Financial Officer Vishwas Setia sold 2,922 shares of MapLight Therapeutics to cover statutory tax obligations.

Chief Scientific Officer James Woodruff sold 4,513 shares of MapLight Therapeutics to cover statutory tax withholding obligations.

Chief Medical Officer Erin Foff sold 3,213 shares of MapLight Therapeutics to cover statutory tax withholding obligations.

CEO Christopher Kroeger sold 19,187 shares of MapLight Therapeutics to cover statutory tax withholding obligations.

MapLight Therapeutics Director Robert C. Malenka sold common stock totaling 14,195 shares to cover tax obligations related to restricted stock unit awards.

MapLight Therapeutics Director George Pavlov acquired 25,000 shares of common stock over three days, signaling increased insider confidence.

MapLight Therapeutics Director Robert C. Malenka sold 12,116 shares of common stock at a weighted average price of $18.21 to cover tax obligations from restricted stock unit awards.

MapLight Therapeutics Director Timothy John Garnett acquired 14,124 shares of common stock for $17.89 each, signaling confidence in the company.

MapLight Therapeutics Director Robert C. Malenka sold common stock to cover tax obligations related to restricted stock unit awards under a Rule 10b5-1 plan.

MapLight Therapeutics' CAAO and PAO, Jonathan Gillis, received significant restricted stock units and stock options.

MapLight Therapeutics' Chief Financial Officer, Vishwas Setia, was granted restricted stock units and employee stock options as part of his compensation.

MapLight Therapeutics' Chief Scientific Officer, James Woodruff Lillie, received an award of 7,730 restricted stock units and 31,395 employee stock options.

MapLight Therapeutics, Inc. awarded its Chief Discovery Officer, Anatol Kreitzer, 6,020 restricted stock units and options to purchase 24,455 shares of common stock.

MapLight Therapeutics, Inc. awarded its General Counsel, Kristopher Hanson, restricted stock units and stock options as part of his compensation.

MapLight Therapeutics' Chief Medical Officer, Erin Pennock Foff, received significant equity awards, including restricted stock units and stock options, on February 5, 2026, aligning her interests with long-term company performance.

MapLight Therapeutics CEO Christopher A. Kroeger acquired 23,145 restricted stock units and 93,955 employee stock options, signaling increased equity alignment.

MapLight Therapeutics Director Robert C. Malenka sold shares to cover tax liabilities related to restricted stock unit awards.

MapLight Therapeutics Director Robert C. Malenka sold 34,398 shares of common stock to cover tax obligations related to restricted stock unit awards.

MapLight Therapeutics' Chief Scientific Officer, James Woodruff Lillie, disposed of 45,055 common shares at $17.98 to cover tax withholding obligations.

MapLight Therapeutics' Chief Discovery Officer, Anatol Kreitzer, disposed of 42,099 common shares to satisfy tax withholding obligations.

MapLight Therapeutics CEO Christopher A. Kroeger reported a disposition of shares to cover tax obligations related to restricted stock unit awards.

MapLight Therapeutics' CAAO and PAO, Jonathan Gillis, disposed of 22,050 shares of common stock to cover tax obligations related to restricted stock unit awards.

MapLight Therapeutics' Chief Medical Officer, Erin Pennock Foff, disposed of 44,616 common shares to cover tax withholding obligations.

MapLight Therapeutics' General Counsel, Kristopher Hanson, disposed of 26,007 shares of common stock to cover tax withholding obligations related to RSU settlement.

Novo Holdings A/S converted preferred shares and purchased additional common stock in MapLight Therapeutics' initial public offering, increasing its beneficial ownership.

Catalyst4, Inc. increased its indirect beneficial ownership in MapLight Therapeutics, Inc. to 19,697,464 voting common shares following an IPO-related conversion of preferred stock and a direct purchase.

MapLight Therapeutics' Chief Financial Officer, Vishwas Setia, was granted 43,367 restricted stock units and options to purchase 176,031 shares of common stock.

MapLight Therapeutics' Chief Medical Officer, Erin Pennock Foff, was granted 48,275 restricted stock units and options to purchase 196,035 shares of common stock.

MapLight Therapeutics Director Robert C. Malenka reported the future acquisition of restricted stock units and employee stock options, alongside the conversion of Series C Preferred Stock into common stock, all under a Rule 10b5-1 plan.

MapLight Therapeutics CEO Christopher A. Kroeger reported significant acquisitions of company stock and options, including 225,693 restricted stock units and 916,164 employee stock options.